By: IPP Bureau
Last updated : December 24, 2025 7:14 pm
The therapy targets the LRRC15 protein and is designed for enhanced tumor penetration and differentiated anti-tumor activity in solid tumors with the highest unmet needs.
Global biopharma Ipsen announced an exclusive licensing agreement with Simcere Zaiming for the global rights (excluding Greater China) to SIM0613, an innovative antibody-drug conjugate (ADC).
The therapy targets the LRRC15 protein and is designed for enhanced tumor penetration and differentiated anti-tumor activity in solid tumors with the highest unmet needs.
“Today’s announcement underscores our bold vision to lead innovation and shape the future of oncology,” said Christelle Huguet, PhD, EVP and Head of Research & Development at Ipsen.
"By advancing first- and best-in-class therapies early, we maximize the potential to transform patient outcomes globally. The addition of the SIM0613 ADC is testament to this ambition—pioneering science that opens new possibilities for those who need it most and builds on Ipsen’s rapidly evolving research and early development portfolio, with over 20 programs added since 2020.”
SIM0613 was developed via Simcere Zaiming’s proprietary ADC platform. “We are excited to partner with Ipsen on this novel drug candidate and look forward to working together to advance the clinical development of SIM0613,” said Renhong Tang, CEO of Simcere Zaiming.
The deal could deliver up to $1.06 billion to Simcere Zaiming through upfront, development, regulatory, and commercial milestone payments, as well as tiered royalties on sales, contingent on regulatory approvals.
Ipsen will handle all activities outside Greater China, including Phase I preparations and the submission of Investigational New Drug and Clinical Trial applications, and will take over manufacturing following the technology transfer.